Mitral valve regurgitation is a common valve disorder that causes blood to leak backward through the mitral valve and into the left atrium as the heart muscle contracts. Mitral regurgitation can originate from degenerative or structural defects due to aging, infection, or congenital anomalies. In contrast, functional mitral regurgitation occurs when coronary artery disease or events such as a heart attack change the size and shape of the heart muscle, preventing the mitral valve from opening and closing properly. In people with moderate to severe mitral regurgitation, the left ventricle works harder to keep up with the body’s demand for oxygenated blood. Over time, this dysfunction can lead to enlargement of the left ventricle, weakening of the myocardium and pulmonary hypertension.

Surgery—either to repair or replace a leaky mitral valve—has been the principal therapeutic option for patients with chronic, severe mitral regurgitation that is not controlled with medication. A less invasive option, which involves transcatheter implantation of a device that essentially sutures the valve leaflets and increases their coaptation, is indicated for patients with severe degenerative mitral regurgitation who are at high risk for conventional heart surgery.

The EVEREST (Endovascular Valve Edge-to-Edge Repair Study) II Trial was a randomized study comparing the transcatheter approach using MitraClip—a tiny cobalt chromium clip that sutures the anterior and posterior mitral valve leaflets—with surgery in patients with moderate to severe mitral regurgitation who are candidates for either procedure. After five years, the study has demonstrated that MitraClip was associated with a similar risk of death compared with mitral valve surgery after excluding patients who required surgery within six months. However, patients who were treated with the MitraClip had a significantly higher rate of residual mitral regurgitation at five years after the procedure compared with those who had surgery (14 percent versus 3 percent).

Another clinical trial, COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation), is now getting underway in 100 U.S. sites. The study will compare transcatheter mitral valve repair with standard therapy—medications, pacemaker implantation, or other treatments—and standard therapy alone in approximately 610 patients.
I have spent time at the hospital for heart failure, and it seemed my condition was getting worse. I was having trouble breathing and could hardly walk around the neighborhood, or even around my home. My valves were the problem, but I was afraid to have a major operation to fix them. During one of my follow-up visits to my cardiologist, he told me they were getting too bad, and he said the doctor to see was Dr. Sharma.

“Everyone at Mount Sinai Hospital was very good and very caring, especially Dr. Sharma.”

“I have spent time at the hospital for heart failure, and it seemed my condition was getting worse. I was having trouble breathing and could hardly walk around the neighborhood, or even around my home. My valves were the problem, but I was afraid to have a major operation to fix them. During one of my follow-up visits to my cardiologist, he told me they were getting too bad, and he said the doctor to see was Dr. Sharma.

“Everyone at Mount Sinai Hospital was very good and very caring, especially Dr. Sharma. Thank God I have great doctors.”

PATIENT: Teresa Kukura, 89-year-old female
DIAGNOSIS: MV insufficiency
TREATMENT: Transcatheter mitral valve repair using MitraClip®

Pre and Post MitraClip Implant